Early Impact of Bevacizumab on the 99m Tc-HYNIC-PSMA-11 Uptake in a Case of Recurrent Glioblastoma Multiforme.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39192507.
- Also identified by DOI 10.1097/RLU.0000000000005435.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glioblastoma multiforme (GBM) is a highly vascularized tumor with reported high prostate-specific membrane antigen (PSMA) expression. On the other hand, bevacizumab as an antiangiogenesis drug is increasingly used in the treatment of GBM recurrence. We present a case of GBM recurrence with significant reduction of 99m Tc-HYNIC-PSMA-11 uptake in her tumor 1 week after administration of 2 doses of bevacizumab with 2 weeks' interval. This case emphasizes the main mechanism of PSMA uptake in GBM secondary to angiogenesis and also implies a potential interaction of bevacizumab with PSMA uptake that should be especially considered during diagnostic and therapeutic application of PSMA radiotracers in GBM.
Medical subject headings
- Glioblastoma
- Bevacizumab
- Organotechnetium Compounds